HILL BARBARA B
Known title: DirectorCIK: 0001235676
Associated companies
Transaction History
| IART | ▲ Buy | Grant | 6,638 | $0 | 5/7/2026 | View on chart |
| IART | ▲ Buy | Grant | 17,700 | $0 | 5/7/2026 | View on chart |
| IART | ▲ Buy | Grant | 6,939 | $0 | 5/9/2025 | View on chart |
| IART | ▲ Buy | Grant | 19,592 | $0 | 5/9/2025 | View on chart |
| IART | ▲ Buy | Open Market | 36,350 | $996K | 5/21/2024 | View on chart |
| IART | ▲ Buy | Grant | 3,163 | $0 | 5/9/2024 | View on chart |
| IART | ▲ Buy | Grant | 8,696 | $0 | 5/9/2024 | View on chart |
| IART | ▲ Buy | Grant | 1,631 | $0 | 5/12/2023 | View on chart |
| IART | ▲ Buy | Grant | 4,486 | $0 | 5/12/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,265 | $0 | 5/13/2022 | View on chart |
| IART | ▲ Buy | Grant | 3,456 | $0 | 5/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.